Lineage Cell Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-20.0M | $33.6M | $-47.0M | $-36.4M | $-43.9M | $-21.4M | $-16.5M | $-11.2M |
| Depreciation & Amortization | $947.0K | $1.2M | $1.1M | $1.1M | — | — | — | — |
| Depreciation | — | — | $1.1M | $1.1M | $657.0K | $386.5K | $373.3K | $138.7K |
| Amortization | $2.3M | $3.6M | $5.3M | $7.4M | $3.3M | $2.4M | $2.0M | $790.1K |
| Stock-Based Compensation | $3.9M | $8.0M | $11.1M | $4.5M | $3.2M | $1.8M | $1.8M | $638.7K |
| Net Cash from Operating Activities | $-30.5M | $-42.3M | $-44.5M | $-38.9M | $-29.5M | $-19.7M | $-13.6M | $-7.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.3M | $2.2M | $1.2M | $483.0K | $2.3M | $400.8K | $960.3K | $220.8K |
| Business Acquisitions | — | — | — | — | $0 | $0 | $246.9K | $0 |
| Net Cash from Investing Activities | $-10.2M | $-10.9M | $-7.4M | — | $-3.7M | $-104.7K | $-1.2M | $3.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $55.4M | $32.8M | $64.8M | — | $34.3M | $1.9M | $3.9M | $25.8M |
| Net Change in Cash | $14.8M | $-20.1M | $12.7M | $24.0M | $1.1M | $-17.9M | $-11.1M | $21.1M |
| Free Cash Flow | $-31.8M | $-44.6M | $-45.8M | $-39.3M | $-31.8M | $-20.1M | $-14.6M | $-8.0M |